- Home
- TWG vs SYBX Comparison
TWG vs SYBX Comparison
Compare TWG & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWG
- SYBX
- Stock Information
- Founded
- TWG 2009
- SYBX N/A
- Country
- TWG Hong Kong
- SYBX United States
- Employees
- TWG 12
- SYBX N/A
- Industry
- TWG
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- TWG
- SYBX Health Care
- Exchange
- TWG NYSE
- SYBX Nasdaq
- Market Cap
- TWG 11.1M
- SYBX 17.0M
- IPO Year
- TWG 2024
- SYBX N/A
- Fundamental
- Price
- TWG $0.21
- SYBX $1.37
- Analyst Decision
- TWG
- SYBX Hold
- Analyst Count
- TWG 0
- SYBX 3
- Target Price
- TWG N/A
- SYBX $1.00
- AVG Volume (30 Days)
- TWG 1.7M
- SYBX 71.5K
- Earning Date
- TWG 02-15-2025
- SYBX 11-12-2024
- Dividend Yield
- TWG N/A
- SYBX N/A
- EPS Growth
- TWG 27.13
- SYBX N/A
- EPS
- TWG 0.09
- SYBX N/A
- Revenue
- TWG $16,943,287.00
- SYBX $2,777,000.00
- Revenue This Year
- TWG N/A
- SYBX N/A
- Revenue Next Year
- TWG N/A
- SYBX N/A
- P/E Ratio
- TWG $2.44
- SYBX N/A
- Revenue Growth
- TWG 99.03
- SYBX 292.23
- 52 Week Low
- TWG $0.17
- SYBX $1.22
- 52 Week High
- TWG $13.50
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- TWG N/A
- SYBX 41.68
- Support Level
- TWG N/A
- SYBX $1.44
- Resistance Level
- TWG N/A
- SYBX $1.88
- Average True Range (ATR)
- TWG 0.00
- SYBX 0.09
- MACD
- TWG 0.00
- SYBX -0.00
- Stochastic Oscillator
- TWG 0.00
- SYBX 1.92
About TWG TOP WEALTH GROUP HLDG LTD
Top Wealth Group Holding Ltd is as supplier of caviar and offer caviar-based gourmet products. It is specialized in supplying high quality sturgeons caviar.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.